Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients - Takeaways - MDSpire

Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients

  • By

  • Katharina Hartman

  • Guido Steiner

  • Cary M. Looney

  • Michel Siegel

  • Katharine Bray-French

  • Klaudia Brix

  • Sebastian Springer

  • Timothy P. Hickling

  • Niels Janssen

  • Axel Ducret

  • Céline Marban-Doran

  • July 7, 2026

Share

  • 1

    The development of anti-drug antibodies (ADAs) can reduce the efficacy and safety of therapeutic monoclonal antibodies (mAbs).

  • 2

    Clinical MAPPs is a miniaturized assay designed to identify MHC-II receptor-associated antibody-derived peptides from low blood volumes.

  • 3

    This assay allows for personalized characterization of peptides before mAb treatment, enhancing immunogenicity risk assessments.

  • 4

    Clinical MAPPs can utilize cryopreserved peripheral blood mononuclear cells, making it suitable for clinical applications.

  • 5

    The assay aims to facilitate monitoring of ADA onset in patients, potentially improving treatment plans tailored to individual needs.

Original Source(s)

Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients

  • by Katharina Hartman, Guido Steiner, Cary M. Looney, Michel Siegel, Katharine Bray-French, Klaudia Brix, Sebastian Springer, Timothy P. Hickling, Niels Janssen, Axel Ducret, Céline Marban-Doran

  • July 7, 2026

Related Content

Case Report: Giant cell reparative granuloma of the humerus and femur—two rare cases with atypical skeletal involvement

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

Breast Cancer Protocols Move Forward

WHO-aligned updates affect synoptic reporting, grading, and tumor characterization

  • July 7, 2026

  • 2 min